2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N9435
    28-Homobrassinolide 82373-95-3
    28-Homobrassinolide is a phytosteroid. 28-Homobrassinolide can be used for the research of cholesterol and glucose homeostasis.
    28-Homobrassinolide
  • HY-103200
    SR59230A hydrochloride 1135278-41-9 99.81%
    SR59230A hydrochloride is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively.
    SR59230A hydrochloride
  • HY-108915
    Trimethylamine N-oxide dihydrate 62637-93-8 ≥98.0%
    Trimethylamine N-oxide dihydrate is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide dihydrate induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide dihydrate also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway.
    Trimethylamine N-oxide dihydrate
  • HY-113080
    N-Acetylornithine 6205-08-9 ≥98.0%
    N-Acetylornithine is a precursor of ornithine. N-Acetylornithine is associated with type 2 diabetes.
    N-Acetylornithine
  • HY-114116
    ML-109 1186649-91-1 ≥98.0%
    ML-109 is a potent and full thyroid stimulating hormone receptor (TSHR) agonist, with an EC50 of 40 nM.
    ML-109
  • HY-13771A
    Ursodeoxycholic acid sodium 2898-95-5 ≥98.0%
    Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active.
    Ursodeoxycholic acid sodium
  • HY-141700
    FATP1-IN-2 2650944-83-3 98.83%
    FATP1-IN-2 (compound 12a), an arylpiperazine derivative, is an orally active fatty acid transport protein 1 (FATP1) inhibitor (human IC50=0.43 μM, mouse IC50=0.39 μM).
    FATP1-IN-2
  • HY-N0593S
    Deoxycholic acid-d4 112076-61-6 ≥98.0%
    Deoxycholic acid-d4 is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.
    Deoxycholic acid-d4
  • HY-P2080B
    GIP (1-30) amide,human acetate 98.24%
    GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human acetate dose-dependently promotes insulin secretion over the range 10-9-10-6 M.
    GIP (1-30) amide,human acetate
  • HY-W010040
    4-​Hydroxyphenylpyruvic acid 156-39-8
    4-Hydroxyphenylpyruvic acid is an intermediate in the metabolism of the amino acid phenylalanine. 4-Hydroxyphenylpyruvic acid is a substrate of 4-hydroxyphenylpyruvic acid dioxygenase. 4-Hydroxyphenylpyruvic acid can be used in the study of HPD-related diseases, such as type III tyrosinemia and hawkinsinuria.
    4-​Hydroxyphenylpyruvic acid
  • HY-15259
    CP-640186 591778-68-6 99.72%
    CP-640186 is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 can also stimulate muscle fatty acid oxidation.
    CP-640186
  • HY-I0352
    Epiandrosterone 481-29-8 ≥98.0%
    Epiandrosterone is a steroid hormone. Epiandrosterone activates BKCa. Epiandrosterone inhibits glucose transport and insulin release. Epiandrosterone has weak androgenic activity.
    Epiandrosterone
  • HY-12584
    PF-5190457 1334782-79-4 ≥98.0%
    PF-5190457 (PF-05190457) is a potent and selective ghrelin receptor inverse agonist with a pKi of 8.36.
    PF-5190457
  • HY-15438
    SB 415286 264218-23-7 99.57%
    SB 415286 is a potent and selective cell permeable inhibitor of GSK-3α, with an IC50 of 77.5 nM, and a Ki of 30.75 nM; SB 415286 is equally effective at inhibiting human GSK-3α and GSK-3β.
    SB 415286
  • HY-12542A
    Dantrolene sodium hemiheptahydrate 24868-20-0 99.79%
    Dantrolene sodium hemiheptahydrate is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium hemiheptahydrate is also a calcium channel protein inhibitor. Dantrolene sodium hemiheptahydrate inhibits the release of Ca2+ from RyR1 and RyR3, which can be beneficial in a variety of pathologies caused by disruptions in calcium homeostasis (e.g., stroke, ischemia/reperfusion injury, and neurodegenerative diseases). Dantrolene sodium hemiheptahydrate offers relief of muscle spasms, malignant hyperthermia, and antitoxic, antipyretic, and anti-inflammatory properties.
    Dantrolene sodium hemiheptahydrate
  • HY-B0287
    Clofibrate 637-07-0 99.61%
    Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ～500 μM for murine PPARα and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.
    Clofibrate
  • HY-B0373
    Tiopronin 1953-02-2 ≥98.0%
    Tiopronin is a diffusible antioxidant, an antidote to heavy metal poisoning and a radioprotective agent. Tiopronin can control the rate of cystine precipitation and excretion and has the potential for cystinuria, rheumatoid arthritis and hepatic disorders.
    Tiopronin
  • HY-131703
    UGT8-IN-1 2414349-93-0 99.94%
    UGT8-IN-1 is a brain penetrable and orally active inhibitor of ceramide galactosyltransferase enzyme (UGT8). UGT8-IN-1 can be used in the study for lysosomal storage disorders.
    UGT8-IN-1
  • HY-12407
    ZK168281 186371-96-0 ≥98.0%
    ZK168281 is a 25-carboxylic ester 1α,25(OH)2D3 analog and a pure VDR antagonist with a Kd value of 0.1 nM. ZK168281 is an effective inhibitor of the coactivator (CoA) interaction of its receptor.
    ZK168281
  • HY-N0073
    Sarsasapogenin 126-19-2 ≥98.0%
    Sarsasapogenin is a sapogenin from the Chinese medical herb Anemarrhena asphodeloides Bunge, with antidiabetic, anti-oxidative, anticancer and anti-inflamatory activities.
    Sarsasapogenin
Cat. No. Product Name / Synonyms Application Reactivity